SG10202006830WA - Treatment of hand eczema - Google Patents

Treatment of hand eczema

Info

Publication number
SG10202006830WA
SG10202006830WA SG10202006830WA SG10202006830WA SG10202006830WA SG 10202006830W A SG10202006830W A SG 10202006830WA SG 10202006830W A SG10202006830W A SG 10202006830WA SG 10202006830W A SG10202006830W A SG 10202006830WA SG 10202006830W A SG10202006830W A SG 10202006830WA
Authority
SG
Singapore
Prior art keywords
treatment
hand eczema
eczema
hand
Prior art date
Application number
SG10202006830WA
Other languages
English (en)
Inventor
Tero Wennberg
Anders Per Sørensen
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55236207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202006830W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of SG10202006830WA publication Critical patent/SG10202006830WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Storage Of Fruits Or Vegetables (AREA)
SG10202006830WA 2016-01-21 2017-01-20 Treatment of hand eczema SG10202006830WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16152215 2016-01-21

Publications (1)

Publication Number Publication Date
SG10202006830WA true SG10202006830WA (en) 2020-08-28

Family

ID=55236207

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202006830WA SG10202006830WA (en) 2016-01-21 2017-01-20 Treatment of hand eczema
SG11201805394QA SG11201805394QA (en) 2016-01-21 2017-01-20 Treatment of hand eczema

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201805394QA SG11201805394QA (en) 2016-01-21 2017-01-20 Treatment of hand eczema

Country Status (31)

Country Link
US (3) US20200397787A1 (cg-RX-API-DMAC10.html)
EP (2) EP4257205A3 (cg-RX-API-DMAC10.html)
JP (1) JP6929860B2 (cg-RX-API-DMAC10.html)
KR (2) KR20180102662A (cg-RX-API-DMAC10.html)
CN (3) CN117159553A (cg-RX-API-DMAC10.html)
AU (3) AU2017209932A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018014769A2 (cg-RX-API-DMAC10.html)
CA (1) CA3010547A1 (cg-RX-API-DMAC10.html)
CY (2) CY1126388T1 (cg-RX-API-DMAC10.html)
DK (1) DK3405197T3 (cg-RX-API-DMAC10.html)
ES (1) ES2963784T3 (cg-RX-API-DMAC10.html)
FI (2) FI3405197T3 (cg-RX-API-DMAC10.html)
FR (1) FR24C1053I2 (cg-RX-API-DMAC10.html)
HR (1) HRP20231448T1 (cg-RX-API-DMAC10.html)
HU (2) HUE064192T2 (cg-RX-API-DMAC10.html)
IL (4) IL320757A (cg-RX-API-DMAC10.html)
LT (2) LT3405197T (cg-RX-API-DMAC10.html)
MX (2) MX394358B (cg-RX-API-DMAC10.html)
NL (1) NL301306I2 (cg-RX-API-DMAC10.html)
NO (1) NO2024058I1 (cg-RX-API-DMAC10.html)
PL (1) PL3405197T3 (cg-RX-API-DMAC10.html)
PT (1) PT3405197T (cg-RX-API-DMAC10.html)
RS (1) RS64798B1 (cg-RX-API-DMAC10.html)
RU (1) RU2018130097A (cg-RX-API-DMAC10.html)
SG (2) SG10202006830WA (cg-RX-API-DMAC10.html)
SI (1) SI3405197T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202300415T1 (cg-RX-API-DMAC10.html)
TW (2) TWI783921B (cg-RX-API-DMAC10.html)
UA (1) UA123780C2 (cg-RX-API-DMAC10.html)
WO (1) WO2017125523A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201804098B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3968997T3 (fi) * 2019-05-15 2026-06-09 Leo Pharma As Delgositinibin formulaatio voiteen muodossa
CA3210150A1 (en) * 2021-02-02 2022-08-11 Pfizer Inc. Dosing regime for treatment of chronic hand eczema
KR20240027044A (ko) * 2021-07-30 2024-02-29 일라이 릴리 앤드 캄파니 바리시티닙을 사용한 손 습진의 치료
JP2026509302A (ja) 2023-03-17 2026-03-17 レオ ファーマ アクティーゼルスカブ 中等症ないし重症の慢性手湿疹を有する患者における慢性手湿疹を処置する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US20130302298A1 (en) * 2010-11-30 2013-11-14 Bio-K Plus International Inc. Treatment and prevention of eczema
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent

Also Published As

Publication number Publication date
FR24C1053I1 (fr) 2025-02-21
WO2017125523A1 (en) 2017-07-27
SG11201805394QA (en) 2018-08-30
TW201736382A (zh) 2017-10-16
RU2018130097A (ru) 2020-02-21
CN117159554A (zh) 2023-12-05
JP2019502734A (ja) 2019-01-31
MX2018008449A (es) 2018-08-09
TWI841027B (zh) 2024-05-01
US20200397787A1 (en) 2020-12-24
HUS2400045I1 (hu) 2025-01-28
US20230138114A1 (en) 2023-05-04
AU2022252766B2 (en) 2024-08-29
CY2024037I1 (el) 2026-02-25
JP6929860B2 (ja) 2021-09-01
EP3405197A1 (en) 2018-11-28
CN117159553A (zh) 2023-12-05
FIC20240048I1 (fi) 2024-12-19
AU2024266962A1 (en) 2024-12-19
KR20180102662A (ko) 2018-09-17
AU2017209932A1 (en) 2018-07-05
NO2024058I1 (no) 2024-12-13
UA123780C2 (uk) 2021-06-02
ZA201804098B (en) 2024-10-30
HUE064192T2 (hu) 2024-02-28
EP4257205A2 (en) 2023-10-11
NL301306I2 (nl) 2024-12-30
IL260094A (en) 2018-07-31
US20260216193A1 (en) 2026-07-30
LTPA2024538I1 (cg-RX-API-DMAC10.html) 2025-01-10
HRP20231448T1 (hr) 2024-03-01
CN108472297A (zh) 2018-08-31
RU2018130097A3 (cg-RX-API-DMAC10.html) 2020-05-25
TW202332451A (zh) 2023-08-16
EP4257205A3 (en) 2023-12-20
CY1126388T1 (el) 2026-02-25
IL297379A (en) 2022-12-01
NZ743582A (en) 2024-12-20
IL313543A (en) 2024-08-01
LT3405197T (lt) 2023-11-27
CY2024037I2 (el) 2026-02-25
PL3405197T3 (pl) 2024-02-12
EP3405197B1 (en) 2023-09-06
FR24C1053I2 (fr) 2025-12-05
AU2022252766A1 (en) 2022-11-03
IL320757A (en) 2025-07-01
SI3405197T1 (sl) 2024-03-29
CA3010547A1 (en) 2017-07-27
RS64798B1 (sr) 2023-11-30
FI3405197T3 (fi) 2023-11-23
KR20250088666A (ko) 2025-06-17
ES2963784T3 (es) 2024-04-02
BR112018014769A2 (pt) 2018-12-11
TWI783921B (zh) 2022-11-21
PT3405197T (pt) 2023-12-06
SMT202300415T1 (it) 2024-01-10
MX2022005915A (es) 2022-06-27
MX394358B (es) 2025-03-24
DK3405197T3 (da) 2023-11-27

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
PL3504187T3 (pl) Stosowanie pridopidyny w leczeniu zaburzeń czynnościowych
HUE041433T2 (hu) Fibrózis kezelése
IL268694A (en) Treatment of schizophrenia
SG11201609652RA (en) Treatment of polybacterials infections
PT3506904T (pt) Tratamento de demência
SMT202100245T1 (it) Trattamento combinato del cancro
IL263835A (en) Exosome-guided treatment of cancer
HUS2400045I1 (hu) Delgocitinib alkalmazása krónikus kézekcéma kezelésére
IL255498A (en) Treatment of pruritus
GB201408297D0 (en) Treatment of cancer
GB201603546D0 (en) Treatment of urine
LT3504163T (lt) Nuotekų valymas
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201602802D0 (en) Method of treatment
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201512139D0 (en) Methods of treatment
GB201417456D0 (en) Treatment of cancer
GB201622214D0 (en) treatment of cancer
GB201604621D0 (en) Treatment of cancer
GB201604293D0 (en) Treatment of cancer
GB201505633D0 (en) Novel treatment of STIs
GB201512723D0 (en) Treatment of cancer
GB201608599D0 (en) Treatment of opioid tollerence
GB201507928D0 (en) Treatment of cancer